Companies › Shenzhen Salubris Pharmaceuticals
8 active drug programs in 25 registered trials: 13 Phase 2, 6 Phase 1, 4 Phase 4, 2 Phase 3; Cardiovascular, Metabolic and endocrine, Other, Neurology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Losartan Type-1 angiotensin II receptor antagonist | AGTR1 | Phase 4 | Healthy Participants; Atrial Fibrillation; Diabetes Mellitus, Type 2; Heart Valve Diseases … | – |
| SAL056 GLP-1 receptor agonist | – | Phase 2 | Postmenopausal Women With Osteoporosis | Nov 2026 |
| SAL0140 | – | Phase 2 | Uncontrolled Hypertension | Mar 2027 |
| GW906 | – | Phase 2 | Hypertension | – |
| SAL-0951 Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor | – | Phase 2 | Anemia | – |
| SAL0120 | – | Phase 2 | Chronic Kidney Disease | – |
| SAL0133 | – | Phase 1 | Pharmacokinetics | – |
| SAL0137 Lipoprotein(a) [Lp(a)] reduction mechanism unclear | – | Phase 1 | Healthy Participants | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07030504 | SAL0133 | Phase 1 | Pharmacokinetics | Other | Jun 2025 |
| NCT05619653 | Losartan | Phase 3 | COVID-19 Associated Cardiac Involvement | Cardiovascular | Aug 2025 |
| NCT07174830 | Losartan | Phase 4 | Healthy Participants | Other | Dec 2025 |
| NCT06737081 | SAL-0951 | Phase 2 | Anemia | Hematology | Dec 2025 |
| NCT07051603 | SAL0140 | Phase 1 | Uncontrolled Hypertension | Cardiovascular | Jan 2026 |
| NCT07716618 | SAL0120 | Phase 2 | Chronic Kidney Disease | Genitourinary | May 2026 |
| NCT07586371 | Losartan | Phase 2 | Proteinuria | Metabolic and endocrine | Jul 2026 |
| NCT07835971 | GW906 | Phase 2 | Hypertension | Cardiovascular | Sep 2026 |
| NCT07745114 | SAL0137 | Phase 1 | Healthy Participants | Metabolic and endocrine | Sep 2026 |
| NCT07579936 | SAL056 | Phase 2 | Postmenopausal Women With Osteoporosis | Metabolic and endocrine | Nov 2026 |
| NCT01199978 | Losartan | Phase 2 | Vestibular Schwannoma | Oncology | Dec 2026 |
| NCT06211335 | Losartan | Phase 1 | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT04111419 | Losartan | Phase 4 | Atrial Fibrillation | Cardiovascular | Dec 2026 |
| NCT05077800 | Losartan | Phase 2 | Pancreatic Adenocarcinoma | Oncology | Dec 2026 |
| NCT07654140 | SAL0140 | Phase 2 | Uncontrolled Hypertension | Cardiovascular | Mar 2027 |
| NCT02560805 | Losartan | Phase 2 | Stress Disorders, Post-Traumatic | Psychiatry | Mar 2027 |
| NCT03563248 | Losartan | Phase 2 | Pancreatic Cancer | Oncology | Apr 2027 |
| NCT06364176 | Losartan | Phase 2 | Cystic Fibrosis | Respiratory | May 2027 |
| NCT03900793 | Losartan | Phase 1 | Osteosarcoma | Oncology | Aug 2027 |
| NCT05637216 | Losartan | Phase 2 | Radiation Induced Fibrosis | Oncology | Aug 2027 |
| NCT06143566 | Losartan | Phase 1 | Type 2 Diabetes | Metabolic and endocrine | Sep 2027 |
| NCT05331144 | Losartan | Phase 2 | Cognitively Normal Older Adults | Neurology | Jun 2028 |
| NCT03264352 | Losartan | Phase 4 | Diabetes Mellitus, Type 2 | Cardiovascular | Sep 2028 |
| NCT07569640 | Losartan | Phase 3 | Heart Failure With Reduced Ejection Fraction | Cardiovascular | Apr 2029 |
| NCT07099859 | Losartan | Phase 4 | Heart Valve Diseases | Cardiovascular | Jul 2029 |
THPharm HB BioTech Chong Kun Dang Pharmaceutical Yuhan Travere Therapeutics Shin Poong Pharmaceutical Chia Tai Tianqing Pharmaceutical Group
Shin Poong Pharmaceutical JW Pharmaceutical Suzhou Alphamab Shanghai Minwei Biotechnology Fujian Shengdi Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.